insulin lispro

January 2002
Royal Society of Medicine: Medicines;2002, p305
Reference Entry
The article presents information on insulin lispro, a recombinant biosynthetic human insulin analogue, which is used in diabetic treatment to maintain diabetic patients. Insulin lispro is relatively short-acting. Administration is by injection.


Related Articles

  • insulin aspart.  // Royal Society of Medicine: Medicines;2002, p305 

    The article presents information on insulin aspart, a recombinant biosynthetic human insulin analogue, which is used in diabetic treatment to maintain diabetic patients. Insulin aspart has a faster rate of onset and offset of action than soluble insulin. Administration is by injection.

  • Insulin: A Voice for Choice. Teuscher, Arthur // Diabetes Health;Dec2007/Jan2008, Vol. 16 Issue 6, p18 

    The article discusses the dangers of hypoglycemic unawareness in diabetics who are taking human insulin. Human insulin came into use in the 1980s as a more physiological alternative to animal insulin, but some patients however reported a sudden loss of symptoms that had previously warned them...

  • A Case of Suppurative Granuloma Induced by Insulin Injection. Tanizaki, Hideaki; Matsumura, Vumi; Tokura, Yoshiki; Miyachi, Yoshiki; Kabashim, Kenji // Acta Dermato-Venereologica;2010, Vol. 90 Issue 5, p540 

    The article presents a case study of a 76-year-old woman with diabetes mellitus presenting with multiple deep-seated, slightly pruritic, symmetrical skin nodules on the flanks and thighs. She claimed that the lesion appeared two-three days after insulin injections. A skin biopsy of an...

  • Insulin Utopia. Trecroci, Daniel // Diabetes Health;Dec2008/Jan2009, Vol. 17 Issue 6, p7 

    The article discusses the available insulins for every diabetes type. New insulins include a 24-hour insulin called Lantus which was approved in 2001, Levemir approved in 2005, fast-acting insulin called Apidra which was approved in 2004, Humalog, and NovoLog. These insulins were formulated to...

  • YOUR DRUG WAS DISCONTINUED. Weil, Andrew // Time International (South Pacific Edition);5/8/2006, Issue 18, p139 

    The article presents information on issues related to the substitution of animal insulin with the synthetic one. The selling of animal insulin has been terminated in the U.S. from April 1, 2006, and synthetic human insulin, produced by recombinant-DNA technology, have entered the markets....

  • Insulin-producing neurospheres.  // PLoS Medicine;Apr2005, Vol. 2 Issue 4, p269 

    Discusses research being done on the differentiation of insulin-producing cells from human neural progenitor cells. Reference to a study by Seung Kim and colleagues published in this issue; Availability of recombinant insulin; Search for renewable sources of insulin-producing cells through...

  • An alternative insulin for diabetic dogs. Blake, Avi // Veterinary Medicine;Oct2012, Vol. 107 Issue 10, p430 

    The article discusses alternative insulin for dogs with diabetes mellitus in the U.S. It mentions that some of them suffering from the said disease are insufficiently controlled with neutral protamine Hagedorn (NPH) insulin which led veterinarians to search for a longer-acting insulin...

  • Effects of Recombinant Human IGF-I/IGF-Binding Protein-3 Complex on Glucose and Glycerol Metabolism in Type 1 Diabetes. Saukkonen, Tero; Shojaee-Moradie, Fariba; Williams, Rachel M.; Amin, Rakesh; Yuen, Kevin C.; Watts, Angie; Acerini, Carlo L.; Umpleby, A. Margot; Dunger, David B. // Diabetes;Aug2006, Vol. 55 Issue 8, p2365 

    Recombinant human IGF-I (rhIGF-I) complexed with its natural binding protein IGF-binding protein (IGFBP)-3 (rhIGF-I/IGFBP-3) is a novel formulation that has been shown to improve insulin sensitivity in type 1 diabetes, yet the mechanisms are not clear. We used stable isotopes to investigate the...

  • Pathophysiology of Recombinant Human Insulin-Induced Local Lipoatrophy. Ximena Lopez; Castells, Mariana C.; Velazquez, Elsa F.; Ricker, Alyne; Lin, Debby A.; Mun, Edward C.; Goldfine, Allison B. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA158 

    Insulin-induced lipoatrophy has become uncommon after the introduction of purified recombinant human insulin. It can be cosmetically devastating and the loss of subcutaneous tissue sites for insulin administration complicates therapy. We report 5 cases of local lipoatrophy associated with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics